Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Opinion: Digging into the IgAN landscape with a focus on Travere's Filspari (sparsentan), Calliditas' Nefecon (Tarpeyo/Kinpeygo), and Chinook's Atrasentan

Ticker(s): CALT, TVTX, KDNY

Who's the expert?

Institution: Johns Hopkins

Professor of Medicine at Johns Hopkins University School of Medicine & Director of the VHL Clinical Care Center at Johns Hopkins
Treats CKD patients not on dialysis and on dialysis. 90% of dialysis patients are on anemia treatment.
Has participated as principal investigator in several studies and research focuses on Acute Kidney Injury (AKI), Chronic Kidney Disease, Fabry Disease, Glomerulonephritis, HIV Related Kidney Disease.

Interview Goal

This call will focus on the FDA approval of Travere's Filspari (sparsentan), Calliditas' Nefecon (Tarpeyo/Kinpeygo), and the results from the phase 3 ALIGN study regarding Chinook's Atrasentan. This call will also compare and contrast all three medications potential for treatment of IgA Nephropathy.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.